TAIPEI, Taiwan – Astrazeneca plc said recently it would make a TWD1 billion (US$32.5 million) R&D investment in Taiwan over the coming three years, nearly tripling its clinical R&D spending. The company said that investment will drive the roll-out of 10 new medicines by 2021, which will target ovarian cancer, lung cancer, severe asthma and diabetes.
TAIPEI, Taiwan – Astrazeneca plc said this week it would make a TWD1 billion (US$32.5 million) R&D investment in Taiwan over the coming three years, nearly tripling its clinical R&D spending. The company said that investment will drive the roll-out of 10 new medicines by 2021, which will target ovarian cancer, lung cancer, severe asthma and diabetes.
TAIPEI, Taiwan – Precision medicine was a big topic at BioTaiwan, with one very local case study highlighting the promise of both the evolving field, as well as Taiwan's role as a clinical research location – a role the government is seeking to expand.
TAIPEI, Taiwan – The topic of where technology will take health care in the near future was approached from numerous perspectives on the first day of BioTaiwan. While long-term questions such as what tasks will remain for humans were harder to answer, there was more certainty about the changes that are on the horizon.
TAIPEI, Taiwan – Precision medicine was a big topic at BioTaiwan, with one very local case study highlighting the promise of both the evolving field, as well as Taiwan's role as a clinical research location – a role the government is seeking to expand.
TAIPEI, Taiwan – The topic of where technology will take health care in the near future was approached from numerous perspectives on the first day of BioTaiwan. While long-term questions such as what tasks will remain for humans were harder to answer, there was more certainty about the changes that are on the horizon.
TAIPEI, Taiwan – Artificial intelligence is already changing health care, but the revolution is only just beginning, and within the coming decade it will have completely transformed the biotech industry as we know it.
TAIPEI, Taiwan – Taiwan's biopharma industry faces strong competition from both China and South Korea, but its geographic position on the edge of Southeast Asia provides an advantage in marketing a potential dengue vaccine to the young and fast-growing region.
TAIPEI, Taiwan – One of the more interesting questions in biopharma today is the direction in which the biosimilars market is headed. Speaking at the recent BioBusiness Asia Conference, part of BioTaiwan 2017, industry insiders shared their views on the outlook for this market, highlighting the state of flux and uncertainty that still defines the segment.
